China

Clover Biopharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Brazil's Health Regulator Greenlights Trials of New Chinese Vaccine

Lead Product(s): SCB-2019 antigen,CpG 1018,Aluminum Hydroxide

Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2021

Details:

First participants have been dosed in Clover’s SPECTRA trial, a global Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of Clover’s protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum.

Clover Biopharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Clover Biopharmaceuticals Raises $230 Million in Oversubscribed Series C Financing

Lead Product(s): SCB-2019 Antigen,CpG 1018,Aluminum Hydroxide

Therapeutic Area: Infections and Infectious Diseases Product Name: SCB-2019

Highest Development Status: Phase II/ Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: GL Ventures

Deal Size: $230.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing February 23, 2021

Details:

The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag© technology platform.